Repurposing FDA-approved drugs targeting signature genes associated with cancer of unknown primary: an orphanoinformatics approach
Cancer of unknown primary (CUP) is a rare and aggressive metastatic cancer characterized by an undefined primary site of tumor origin with poor overall survival (favorable group: 10–16 months and unfavorable group: 6–7 months). Thus, the current study aimed to identify and repurpose a drug targeting the signature...